AlphAIAlphAI — Financial news for AI agents
tipranks.comSEP 102 min read$ELV

Elevance Health Reaffirms 2026 Earnings and Cost Guidance - TipRanks.com

Elevance Health (ELV) reaffirmed its 2026 earnings guidance, projecting at least $20.10 per diluted share, including $6.90 per share of net unfavorable items, and at least $27.00 per diluted share on an adjusted basis. The company also reiterated its 2026 benefit expense ratio guidance at 90.2%, plus or minus 50 basis points, demonstrating confidence in cost control and earnings visibility. Analysts have mixed views, with a recent Buy rating and $488.00 price target, while TipRanks' AI Analyst r

Original reporting
tipranks.com
Published Sep 10, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ELV
Neutral
high confidence
Mentioned
$ELV
Relevance
8/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$ELVNeutralMed
01

Why it matters

The reaffirmation signals management confidence but offers no upside, likely keeping the stock range‑bound in the short term.

02

Market read

Guidance reaffirmation is a material earnings‑related update for a large‑cap insurer, offering modest trading relevance.

03

What to watch

Potential regulatory changes or Medicaid funding shifts could affect profitability despite current guidance.

Relevance 8/10Novelty 8/10Timing: today

Background

Elevance Health (ELV) is a major U.S. health‑benefits insurer that regularly updates guidance based on cost trends and policy environment.

Company-level read

Ticker impact

$ELVNeutralHigh confidence
Context

Elevance Health reaffirmed its full‑year 2026 earnings guidance at $20.10 per diluted share (adjusted $27.00) and benefit expense ratio at 90.2%±50 bps.

Expected impact

Limited upside unless guidance is upgraded; price likely to trade within current range.

Evidence & confidence

Guidance numbers are new and material for a large‑cap health insurer, but no change from prior outlook, reducing immediate trade impetus.

Market effects

Sector

Reaffirmed guidance may bolster confidence in the managed‑care sector, supporting peers like UnitedHealth and Cigna.

Regional

U.S. health‑benefits market sees stable outlook; no immediate regional ripple.

Global

Limited global impact; primarily U.S. health‑insurance investors.

Counterpoint

What could challenge this read

If cost pressures intensify, the 90.2% expense ratio could be breached, leading to earnings miss.

Key entities

  • company
    Elevance Health, Inc.

    U.S. health‑benefits insurer providing coverage and pharmacy services.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 10
$ELVHighAI 8/10

Why is Elevance Health stock surging today?

Elevance Health (ELV) stock rose 5.8% to $418.21 after reaffirming its 2026 adjusted earnings guidance of at least $27.00 per share and signaling Q3 EPS is tracking ahead of expectations. The company also maintained its 2026 operating cash flow target of $6 billion and a 12% adjusted EPS growth target for 2027. Today is the ex-dividend date for its $1.72 per share quarterly dividend.

investing.com2 min
SEP 10
$ELVMedAI 8/10

Elevance holds loss ratio guidance above 90% as fall renewals near

Elevance Health reaffirmed its 2026 benefit expense ratio guidance at 90.2% (+/- 0.5%), indicating stable medical utilization and specialty pharmacy costs. The company expects to meet its adjusted earnings guidance of at least $27 per diluted share. Q2 2026 results showed an 89.7% ratio, up 0.8% YoY, driven by government business costs. Elevance, the second-largest US health insurer, processes pharmacy claims through Carelon. Steady ratio signals heavy claims payouts, impacting fall renewals.

insurancebusinessmag.com2 min
SEP 10
$ELVHighAI 8/10

Elevance Health reaffirms 2026 earnings and benefit expense guidance

Elevance Health (ELV) reaffirmed its 2026 earnings guidance of at least $20.10 per diluted share, including $6.90 in net unfavorable items, and adjusted earnings of at least $27.00 per share. The company also confirmed its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. This follows strong Q2 2026 results, with adjusted earnings of $7.45 per share and revenue of $49.8 billion, but shares faced pressure due to Medicaid concerns. Analysts have mixed price targets and ra

investing.com2 min
SEP 10
$ELVLow

Elevance Health Inc (ELV) Stock News & Articles

Elevance Health (ELV) stock surged after CMS finalized a 2.48% Medicare Advantage payment rate increase for 2027, above expectations. Evercore ISI reinstated ELV with an 'Inline' rating, questioning if the bounce is priced in. The company offers health plans, specialty insurance, and pharmacy services.

247wallst.com2 min